-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Short Interest Down 49.3% in August
Calliditas Therapeutics AB (Publ) (NASDAQ:CALT) Short Interest Down 49.3% in August
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 3,600 shares, a decrease of 49.3% from the August 15th total of 7,100 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is presently 0.8 days.
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
An institutional investor recently raised its position in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC grew its holdings in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after buying an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent SEC filing. Institutional investors own 2.94% of the company's stock.
Get Calliditas Therapeutics AB (publ) alerts:Calliditas Therapeutics AB (publ) Stock Performance
Calliditas Therapeutics AB (publ) stock opened at $15.95 on Thursday. The stock has a market cap of $471.73 million, a P/E ratio of -6.40 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $18.07 and a 200-day moving average of $17.74. Calliditas Therapeutics AB has a 52 week low of $12.55 and a 52 week high of $27.50.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on CALT shares. Kepler Capital Markets started coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 16th. They issued a "buy" rating for the company. TheStreet cut Calliditas Therapeutics AB (publ) from a "c-" rating to a "d" rating in a report on Tuesday, September 6th. Finally, Pareto Securities assumed coverage on Calliditas Therapeutics AB (publ) in a report on Thursday, June 2nd. They issued a "buy" rating for the company.About Calliditas Therapeutics AB (publ)
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Featured Articles
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 3,600 shares, a decrease of 49.3% from the August 15th total of 7,100 shares. Based on an average trading volume of 4,300 shares, the days-to-cover ratio is presently 0.8 days.
卡利迪塔斯治疗公司(PUBL)(纳斯达克代码：CALT-GET评级)是8月份空头股数销量大幅下降的接受者。截至8月31日，空头股数共有3600股，比8月15日的7100股减少了49.3%。以4,300股的平均成交量计算，目前天数与回补比率为0.8天。
Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)
对冲基金买入Calliditas Treateutics AB(Publ)
An institutional investor recently raised its position in Calliditas Therapeutics AB (publ) stock. Ironwood Investment Management LLC grew its holdings in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) by 5.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,762 shares of the company's stock after buying an additional 1,495 shares during the quarter. Ironwood Investment Management LLC owned 0.11% of Calliditas Therapeutics AB (publ) worth $551,000 as of its most recent SEC filing. Institutional investors own 2.94% of the company's stock.
一家机构投资者最近提高了对Calliditas Treateutics AB(Publ)股票的头寸。根据最近提交给美国证券交易委员会的13F文件，铁木投资管理公司在第一季度增持了Calliditas Treateutics AB(Publ)(纳斯达克代码：CALT-GET评级)的股票5.5%。该基金在本季度额外购买了1,495股后，持有该公司28,762股股票。截至最近提交给美国证券交易委员会的文件，Ironwood Investment Management LLC拥有Calliditas Treateutics AB(Publ)0.11%的股份，价值551,000美元。机构投资者持有该公司2.94%的股票。
Calliditas Therapeutics AB (publ) Stock Performance
Calliditas Treateutics AB(Publ)股票表现
Calliditas Therapeutics AB (publ) stock opened at $15.95 on Thursday. The stock has a market cap of $471.73 million, a P/E ratio of -6.40 and a beta of 1.63. The company has a current ratio of 5.32, a quick ratio of 5.32 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $18.07 and a 200-day moving average of $17.74. Calliditas Therapeutics AB has a 52 week low of $12.55 and a 52 week high of $27.50.
周四，Calliditas Treateutics AB(Publ)的股票开盘报15.95美元。该股市值为4.7173亿美元，市盈率为-6.40，贝塔系数为1.63。该公司的流动比率为5.32，速动比率为5.32，债务权益比率为0.64。该股的50日移动均线切入位为18.07美元，200日移动均线切入位为17.74美元。Calliditas Treateutics AB的52周低点为12.55美元，52周高点为27.50美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
About Calliditas Therapeutics AB (publ)
关于Calliditas Treateutics AB(Publ)
(Get Rating)
(获取评级)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Calliditas Treateutics AB(Publ)是一家临床阶段的生物制药公司，专注于识别、开发和商业化用于孤儿适应症治疗的药物产品，最初的重点是肾脏和肝脏疾病。它提供Nefecon，一种口服布地奈德制剂，是一种治疗自身免疫性肾病免疫球蛋白A肾病的免疫抑制剂。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- 免费获取StockNews.com关于Calliditas Treateutics AB(Publ)(CALT)的研究报告
- 这家医疗设备制造商准备好继续反弹了吗？
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马？
- 具有有趣内幕活动的四只廉价股票
- 随着收购传言的甚嚣尘上，Lyft能否成功？
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Calliditas Treateutics AB(Publ)Daily的新闻和评级-在下面输入您的电子邮件地址，以通过MarketBeat.com的免费每日电子邮件时事通讯接收对Calliditas Treateutics AB(Publ)和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧